Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selgantolimod in virally-suppressed chronic hepatitis B
NCT03491553Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of selgantolimod in Chronic Hepatitis B (CHB) (6 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With >= 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at 24 weeks. Started Apr 2018; status: completed.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03491553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491553.